Table 1.
Malignant breast masses
| Sample ID | Histology | Pertinent Receptor status | Size of mass (cm) | MDK/DNA ratio (ng/μg) | PTN/DNA ratio (ng/μg) |
|---|---|---|---|---|---|
| B4–1 |
IDC | ER+, PR+, HER2- | 0.4 | 0.41 | 0 |
| B7–2 |
IDC | ER+, PR+, HER2- | 0.5 | 0.70 | 1.08 |
| B9–1 | DCIS | ER+, PR+ | 0.9 | 0.17 | 0 |
| B9–2 B23–1 |
DCIS LCIS |
ER+, PR+ ER-, PR- |
1.1 0.8 |
0.36 NA |
0 19.0 |
| B41–1 | IDC | ER+, PR+, HER2- | 0.5 | 0.10 | NA |
| B43–1 | IDC | ER+, PR+, HER2- | 0.5 | 0.13 | NA |
| B44–1 | DCIS | ER+, PR+ | 1.1 | 0.13 | NA |
| B44–2 | DCIS | ER+, PR+ | 0.5 | 0.35 | NA |
| B53–1 | DCIS | ER+, PR+ | 0.6 | 0.85 | 1.44 |
| B60–1 | DCIS | ER-, PR- | 0.4 | 0.24 | 0.86 |
| B62–1 | ILC | ER+, PR+, HER2 equivocal | 1.9 | 0.15 | 0 |
| B63–1 | DCIS | ER-, PR- | 0.5 | 0.41 | 0 |
| B73–1 | IDC | ER+, PR+, HER2- | 0.6 | 0.13 | 0 |
| B75–1 | DCIS | ER+, PR- | 2.0 | 0.29 | 1.48 |
| B81–1 | IDC | ER+, PR+, HER2- | 0.4 | 0.30 | 0 |
| B81–2 | IDC | ER+, PR+, HER2- | 0.5 | NA | 0 |
IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ; ILC, invasive lobular carcinoma; LCIS, lobular carcinoma in situ; NA, not available